Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB289 vs TMP-SMX for Acute PCP in HIV/AIDS
NCT00302341Phase 3Terminated
- Sponsor
- Immtech Pharmaceuticals, Inc.
- Start
- May 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pafuramidine in Pneumocystis jirovecii pneumonia (PCP) (2 arms), sponsored by Immtech Pharmaceuticals, Inc. Primary endpoint: Clinical Success at End of Treatment at Day 22. Started May 2006; status: terminated.
02
Drugs
pafuramidine
03
Conditions
Pneumocystis jirovecii pneumonia (PCP)
Beyond the preview
Go deeper on NCT00302341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302341.